Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
The capital expansion program commenced in June 2022 and is expected to complete in 2024
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.
The book “Science behind Suryanamaskar” has been compiled by the AIIA’s Department of Swasthavritta and Yoga.
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
Subscribe To Our Newsletter & Stay Updated
